Systematic Aβ analysis in drosophila reveals high toxicity for the 1-42, 3-42 and 11-42 peptides, and emphasizes N-and C-terminal residues

PLoS ONE

Volumn 10, Issue 7, 2015, Pages

  Jonson, Maria ^a   Pokrzywa, Malgorzata ^a,b   Starkenberg, Annika ^a   Hammarstrom, Per ^a   Thor, Stefan ^a  

^a LINKÖPING UNIVERSITY   (Sweden)

^b Department of Physics Chemistry and Biology Linkoping University ^*  (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-42]; AMYLOID BETA PROTEIN[11-42]; AMYLOID BETA PROTEIN[3-42]; PROTEIN VARIANT; PYROGLUTAMIC ACID; UNCLASSIFIED DRUG; DROSOPHILA PROTEIN; GAL4 PROTEIN, DROSOPHILA; SIGNAL PEPTIDE; TRANSCRIPTION FACTOR;

ADULT; AMINO TERMINAL SEQUENCE; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; IN VITRO STUDY; IN VIVO STUDY; LIFESPAN; MOTOR DYSFUNCTION; MUTATION; NEUROTOXICITY; NONHUMAN; PROTEIN AGGREGATION; PROTEIN EXPRESSION; TRANSGENIC DROSOPHILA; AMINO ACID SEQUENCE; ANIMAL; CHEMISTRY; DROSOPHILA; GENE EXPRESSION; GENETICS; GENOTYPE; LOCOMOTION; METABOLISM; MOLECULAR GENETICS; PROTEINOSIS; SOLUBILITY; TRANSGENIC ANIMAL;

AMINO ACID SEQUENCE; AMYLOID BETA-PEPTIDES; ANIMALS; ANIMALS, GENETICALLY MODIFIED; DROSOPHILA; DROSOPHILA PROTEINS; GENE EXPRESSION; GENOTYPE; LOCOMOTION; MOLECULAR SEQUENCE DATA; PROTEIN AGGREGATION, PATHOLOGICAL; PROTEIN SORTING SIGNALS; SOLUBILITY; TRANSCRIPTION FACTORS;

EID: 84941244984     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0133272     Document Type: Article

References (58)

1. Ferri CP, Prince M, Brayne C, Brodaty H, Fratiglioni L, Ganguli M, et al. Global prevalence of dementia: a Delphi consensus study. Lancet. 2005; 366(9503): 2112-7. Epub 2005/12/20. doi: 10.1016/S0140-6736(05)67889-0 PMID: 16360788; PubMed Central PMCID: PMC2850264.
2. Glenner GG, Wong CW. Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochemical and biophysical research communications. 1984; 120(3): 885-90. Epub 1984/05/16. PMID: 6375662.
3. Masters CL, Simms G, Weinman NA, Multhaup G, McDonald BL, Beyreuther K. Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proceedings of the National Academy of Sciences of the United States of America. 1985; 82(12): 4245-9. Epub 1985/06/01. PMID: 3159021; PubMed Central PMCID: PMC397973.
4. Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta neuropathologica. 1991; 82(4): 239-59. Epub 1991/01/01. PMID: 1759558.
5. Karran E, Mercken M, De Strooper B. The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics. Nature reviews Drug discovery. 2011; 10(9): 698-712. Epub 2011/08/20. doi: 10.1038/nrd3505 PMID: 21852788.
6. Liu K, Solano I, Mann D, Lemere C, Mercken M, Trojanowski JQ, et al. Characterization of Aβ11-40/42 peptide deposition in Alzheimer's disease and young Down's syndrome brains: implication of N-terminally truncated Aβ species in the pathogenesis of Alzheimer's disease. Acta neuropathologica. 2006; 112(2): 163-74. Epub 2006/07/26. doi: 10.1007/s00401-006-0077-5 PMID: 16865398.
7. Saito T, Suemoto T, Brouwers N, Sleegers K, Funamoto S, Mihira N, et al. Potent amyloidogenicity and pathogenicity of Aβ43. Nature neuroscience. 2011; 14(8): 1023-32. Epub 2011/07/05. PMID: 21725313.
8. Schlenzig D, Ronicke R, Cynis H, Ludwig HH, Scheel E, Reymann K, et al. N-Terminal pyroglutamate formation of Aβ38 and Aβ40 enforces oligomer formation and potency to disrupt hippocampal longterm potentiation. Journal of neurochemistry. 2012; 121(5): 774-84. Epub 2012/03/02. doi: 10.1111/j. 1471-4159.2012.07707.x PMID: 22375951.
9. Tekirian TL. Commentary: Aβ N-Terminal Isoforms: Critical contributors in the course of AD pathophysiology. Journal of Alzheimer's disease: JAD. 2001; 3(2): 241-8. Epub 2002/09/06. PMID: 12214065.
10. Crowther DC, Kinghorn KJ, Miranda E, Page R, Curry JA, Duthie FA, et al. Intraneuronal Aβ, non-amyloid aggregates and neurodegeneration in a Drosophila model of Alzheimer's disease. Neuroscience. 2005; 132(1): 123-35. Epub 2005/03/23. doi: 10.1016/j.neuroscience.2004.12.025 PMID: 15780472.
11. Iijima K, Liu HP, Chiang AS, Hearn SA, Konsolaki M, Zhong Y. Dissecting the pathological effects of human Aβ40 and Aβ42 in Drosophila: a potential model for Alzheimer's disease. Proceedings of the National Academy of Sciences of the United States of America. 2004; 101(17): 6623-8. Epub 2004/04/08. doi: 10.1073/pnas.0400895101 PMID: 15069204; PubMed Central PMCID: PMC404095.
12. Bilen J, Bonini NM. Drosophila as a model for human neurodegenerative disease. Annual review of genetics. 2005; 39: 153-71. Epub 2005/11/16. doi: 10.1146/annurev.genet.39.110304.095804 PMID: 16285856.
13. Caesar I, Jonson M, Nilsson KP, Thor S, Hammarstrom P. Curcumin promotes A-β fibrillation and reduces neurotoxicity in transgenic Drosophila. PloS one. 2012; 7(2): e31424. Epub 2012/02/22. doi: 10.1371/journal.pone.0031424 PMID: 22348084; PubMed Central PMCID: PMC3278449.
14. Luheshi LM, Tartaglia GG, Brorsson AC, Pawar AP, Watson IE, Chiti F, et al. Systematic in vivo analysis of the intrinsic determinants of amyloid B pathogenicity. PLoS biology. 2007; 5(11): e290. Epub 2007/11/02. doi: 10.1371/journal.pbio.0050290 PMID: 17973577; PubMed Central PMCID: PMC2043051.
15. Davis S, Laroche S. What can rodent models tell us about cognitive decline in Alzheimer's disease? Molecular neurobiology. 2003; 27(3): 249-76. Epub 2003/07/08. doi: 10.1385/MN: 27: 3: 249 PMID: 12845151.
16. Bischof J, Maeda RK, Hediger M, Karch F, Basler K. An optimized transgenesis system for Drosophila using germ-line-specific phiC31 integrases. Proceedings of the National Academy of Sciences of the United States of America. 2007; 104(9): 3312-7. Epub 2007/03/16. doi: 10.1073/pnas.0611511104 PMID: 17360644; PubMed Central PMCID: PMC1805588.
17. Groth AC, Fish M, Nusse R, Calos MP. Construction of transgenic Drosophila by using the site-specific integrase from phage phiC31. Genetics. 2004; 166(4): 1775-82. Epub 2004/05/06. PMID: 15126397; PubMed Central PMCID: PMC1470814.
18. Finelli A, Kelkar A, Song HJ, Yang H, Konsolaki M. A model for studying Alzheimer's Aβ42-induced toxicity in Drosophila melanogaster. Molecular and cellular neurosciences. 2004; 26(3): 365-75. Epub 2004/07/06. doi: 10.1016/j.mcn.2004.03.001 PMID: 15234342.
19. Lin DM, Goodman CS. Ectopic and increased expression of Fasciclin II alters motoneuron growth cone guidance. Neuron. 1994; 13(3): 507-23. Epub 1994/09/01. PMID: 7917288.
20. Berger C, Renner S, Luer K, Technau GM. The commonly used marker ELAV is transiently expressed in neuroblasts and glial cells in the Drosophila embryonic CNS. Developmental dynamics: an official publication of the American Association of Anatomists. 2007; 236(12): 3562-8. Epub 2007/11/13. doi: 10.1002/dvdy.21372 PMID: 17994541.
21. Crowther DC, Kinghorn KJ, Page R, Lomas DA. Therapeutic targets from a Drosophila model of Alzheimer's disease. Current opinion in pharmacology. 2004; 4(5): 513-6. Epub 2004/09/08. doi: 10.1016/j. coph.2004.07.001 PMID: 15351357.
22. Berg I, Thor S, Hammarstrom P. Modeling familial amyloidotic polyneuropathy (Transthyretin V30M) in Drosophila melanogaster. Neuro-degenerative diseases. 2009; 6(3): 127-38. Epub 2009/04/18. doi: 10.1159/000213761 PMID: 19372706.
23. Vandersteen A, Masman MF, De Baets G, Jonckheere W, van der Werf K, Marrink SJ, et al. Molecular plasticity regulates oligomerization and cytotoxicity of the multipeptide-length amyloid-β peptide pool. The Journal of biological chemistry. 2012; 287(44): 36732-43. Epub 2012/09/21. doi: 10.1074/jbc. M112.394635 PMID: 22992745; PubMed Central PMCID: PMC3481277.
24. Jahn TR, Kohlhoff KJ, Scott M, Tartaglia GG, Lomas DA, Dobson CM, et al. Detection of early locomotor abnormalities in a Drosophila model of Alzheimer's disease. Journal of neuroscience methods. 2011; 197(1): 186-9. Epub 2011/02/15. doi: 10.1016/j.jneumeth.2011.01.026 PMID: 21315762; PubMed Central PMCID: PMC3712187.
25. Aslund A, Sigurdson CJ, Klingstedt T, Grathwohl S, Bolmont T, Dickstein DL, et al. Novel pentameric thiophene derivatives for in vitro and in vivo optical imaging of a plethora of protein aggregates in cerebral amyloidoses. ACS chemical biology. 2009; 4(8): 673-84. Epub 2009/07/25. doi: 10.1021/cb900112v PMID: 19624097; PubMed Central PMCID: PMC2886514.
26. Berg I, Nilsson KP, Thor S, Hammarstrom P. Efficient imaging of amyloid deposits in Drosophila models of human amyloidoses. Nature protocols. 2010; 5(5): 935-44. Epub 2010/05/01. PMID: 20431539.
27. David DC, Ollikainen N, Trinidad JC, Cary MP, Burlingame AL, Kenyon C. Widespread protein aggregation as an inherent part of aging in C. elegans. PLoS biology. 2010; 8(8): e1000450. Epub 2010/08/17. doi: 10.1371/journal.pbio.1000450 PMID: 20711477; PubMed Central PMCID: PMC2919420.
28. Schilling S, Zeitschel U, Hoffmann T, Heiser U, Francke M, Kehlen A, et al. Glutaminyl cyclase inhibition attenuates pyroglutamate Aβ and Alzheimer's disease-like pathology. Nature medicine. 2008; 14 (10): 1106-11. Epub 2008/10/07. PMID: 18836460.
29. Schilling S, Lauber T, Schaupp M, Manhart S, Scheel E, Bohm G, et al. On the seeding and oligomerization of pGlu-amyloid peptides (in vitro). Biochemistry. 2006; 45(41): 12393-9. Epub 2006/10/13. doi: 10.1021/bi0612667 PMID: 17029395.
30. Schoonenboom NS, Mulder C, Van Kamp GJ, Mehta SP, Scheltens P, Blankenstein MA, et al. Amyloid β 38, 40, and 42 species in cerebrospinal fluid: more of the same? Annals of neurology. 2005; 58 (1): 139-42. Epub 2005/06/29. doi: 10.1002/ana.20508 PMID: 15984010.
31. Wiltfang J, Esselmann H, Bibl M, Smirnov A, Otto M, Paul S, et al. Highly conserved and disease-specific patterns of carboxyterminally truncated Aβ peptides 1-37/38/39 in addition to 1-40/42 in Alzheimer's disease and in patients with chronic neuroinflammation. Journal of neurochemistry. 2002; 81 (3): 481-96. Epub 2002/06/18. PMID: 12065657.
32. Elder GA, Gama Sosa MA, De Gasperi R. Transgenic mouse models of Alzheimer's disease. The Mount Sinai journal of medicine, New York. 2010; 77(1): 69-81. Epub 2010/01/27. doi: 10.1002/msj. 20159 PMID: 20101721; PubMed Central PMCID: PMC2925685.
33. Philipson O, Lord A, Gumucio A, O'Callaghan P, Lannfelt L, Nilsson LN. Animal models of amyloid-β-related pathologies in Alzheimer's disease. The FEBS journal. 2010; 277(6): 1389-409. Epub 2010/02/09. doi: 10.1111/j.1742-4658.2010.07564.x PMID: 20136653.
34. Radde R, Bolmont T, Kaeser SA, Coomaraswamy J, Lindau D, Stoltze L, et al. Aβ42-driven cerebral amyloidosis in transgenic mice reveals early and robust pathology. EMBO reports. 2006; 7(9): 940-6. Epub 2006/08/15. doi: 10.1038/sj.embor.7400784 PMID: 16906128; PubMed Central PMCID: PMC1559665.
35. McGowan E, Pickford F, Kim J, Onstead L, Eriksen J, Yu C, et al. Aβ42 is essential for parenchymal and vascular amyloid deposition in mice. Neuron. 2005; 47(2): 191-9. Epub 2005/07/26. doi: 10.1016/j. neuron.2005.06.030 PMID: 16039562; PubMed Central PMCID: PMC1373682.
36. Wittnam JL, Portelius E, Zetterberg H, Gustavsson MK, Schilling S, Koch B, et al. Pyroglutamate amyloid β (Aβ) aggravates behavioral deficits in transgenic amyloid mouse model for Alzheimer disease. The Journal of biological chemistry. 2012; 287(11): 8154-62. Epub 2012/01/24. doi: 10.1074/jbc.M111. 308601 PMID: 22267726; PubMed Central PMCID: PMC3318696.
37. Saido TC, Yamao-Harigaya W, Iwatsubo T, Kawashima S. Amino-and carboxyl-terminal heterogeneity of β-amyloid peptides deposited in human brain. Neuroscience letters. 1996; 215(3): 173-6. Epub 1996/09/13. PMID: 8899741.
38. D'Arrigo C, Tabaton M, Perico A. N-terminal truncated pyroglutamyl β amyloid peptide Aβpy3-42 shows a faster aggregation kinetics than the full-length Aβ1-42. Biopolymers. 2009; 91(10): 861-73. Epub 2009/06/30. PMID: 19562755. doi: 10.1002/bip.21271
39. Pike CJ, Overman MJ, Cotman CW. Amino-terminal deletions enhance aggregation of β-amyloid peptides in vitro. The Journal of biological chemistry. 1995; 270(41): 23895-8. Epub 1995/10/13. PMID: 7592576.
40. Schilling S, Lindner C, Koch B, Wermann M, Rahfeld JU, von Bohlen A, et al. Isolation and characterization of glutaminyl cyclases from Drosophila: evidence for enzyme forms with different subcellular localization. Biochemistry. 2007; 46(38): 10921-30. Epub 2007/08/29. doi: 10.1021/bi701043x PMID: 17722885.
41. Cao W, Song HJ, Gangi T, Kelkar A, Antani I, Garza D, et al. Identification of novel genes that modify phenotypes induced by Alzheimer's β-amyloid overexpression in Drosophila. Genetics. 2008; 178 (3): 1457-71. Epub 2008/02/05. doi: 10.1534/genetics.107.078394 PMID: 18245849; PubMed Central PMCID: PMC2278065.
42. Burdick D, Soreghan B, Kwon M, Kosmoski J, Knauer M, Henschen A, et al. Assembly and aggregation properties of synthetic Alzheimer's A4/β amyloid peptide analogs. The Journal of biological chemistry. 1992; 267(1): 546-54. Epub 1992/01/05. PMID: 1730616.
43. Jarrett JT, Berger EP, Lansbury PT Jr. The carboxy terminus of the β amyloid protein is critical for the seeding of amyloid formation: implications for the pathogenesis of Alzheimer's disease. Biochemistry. 1993; 32(18): 4693-7. Epub 1993/05/11. PMID: 8490014.
44. Parvathy S, Davies P, Haroutunian V, Purohit DP, Davis KL, Mohs RC, et al. Correlation between Aβx-40-, Aβx-42-, and Aβx-43-containing amyloid plaques and cognitive decline. Archives of neurology. 2001; 58(12): 2025-32. Epub 2001/12/26. PMID: 11735776.
45. Welander H, Franberg J, Graff C, Sundstrom E, Winblad B, Tjernberg LO. Aβ43 is more frequent than Aβ40 in amyloid plaque cores from Alzheimer disease brains. Journal of neurochemistry. 2009; 110 (2): 697-706. Epub 2009/05/22. doi: 10.1111/j.1471-4159.2009.06170.x PMID: 19457079.
46. Burnouf S, Gorsky MK, Dols J, Gronke S, Partridge L. Aβ is neurotoxic and primes aggregation of Aβ in vivo. Acta neuropathologica. 2015. Epub 2015/04/12. doi: 10.1007/s00401-015-1419-y PMID: 25862636.
47. Lu JX, Qiang W, Yau WM, Schwieters CD, Meredith SC, Tycko R. Molecular structure of β-amyloid fibrils in Alzheimer's disease brain tissue. Cell. 2013; 154(6): 1257-68. Epub 2013/09/17. doi: 10.1016/j. cell.2013.08.035 PMID: 24034249; PubMed Central PMCID: PMC3814033.
48. Luhrs T, Ritter C, Adrian M, Riek-Loher D, Bohrmann B, Dobeli H, et al. 3D structure of Alzheimer's amyloid-β(1-42) fibrils. Proceedings of the National Academy of Sciences of the United States of America. 2005; 102(48): 17342-7. Epub 2005/11/19. doi: 10.1073/pnas.0506723102 PMID: 16293696; PubMed Central PMCID: PMC1297669.
49. Olofsson A, Sauer-Eriksson AE, Ohman A. The solvent protection of alzheimer amyloid-β-(1-42) fibrils as determined by solution NMR spectroscopy. The Journal of biological chemistry. 2006; 281(1): 477-83. Epub 2005/10/11. doi: 10.1074/jbc.M508962200 PMID: 16215229.
50. Petkova AT, Ishii Y, Balbach JJ, Antzutkin ON, Leapman RD, Delaglio F, et al. A structural model for Alzheimer's β-amyloid fibrils based on experimental constraints from solid state NMR. Proceedings of the National Academy of Sciences of the United States of America. 2002; 99(26): 16742-7. Epub 2002/12/14. doi: 10.1073/pnas.262663499 PMID: 12481027; PubMed Central PMCID: PMC139214.
51. Schmidt M, Sachse C, Richter W, Xu C, Fandrich M, Grigorieff N. Comparison of Alzheimer Aβ(1-40) and Aβ(1-42) amyloid fibrils reveals similar protofilament structures. Proceedings of the National Academy of Sciences of the United States of America. 2009; 106(47): 19813-8. Epub 2009/10/22. doi: 10. 1073/pnas.0905007106 PMID: 19843697; PubMed Central PMCID: PMC2764733.
52. Kim W, Hecht MH. Generic hydrophobic residues are sufficient to promote aggregation of the Alzheimer's Aβ42 peptide. Proceedings of the National Academy of Sciences of the United States of America. 2006; 103(43): 15824-9. Epub 2006/10/14. doi: 10.1073/pnas.0605629103 PMID: 17038501; PubMed Central PMCID: PMC1635087.
53. Bitan G, Kirkitadze MD, Lomakin A, Vollers SS, Benedek GB, Teplow DB. Amyloid β-protein (Aβ) assembly: Aβ 40 and Aβ 42 oligomerize through distinct pathways. Proceedings of the National Academy of Sciences of the United States of America. 2003; 100(1): 330-5. Epub 2002/12/31. doi: 10.1073/pnas.222681699 PMID: 12506200; PubMed Central PMCID: PMC140968.
54. Bitan G, Vollers SS, Teplow DB. Elucidation of primary structure elements controlling early amyloid β-protein oligomerization. The Journal of biological chemistry. 2003; 278(37): 34882-9. Epub 2003/07/04. doi: 10.1074/jbc.M300825200 PMID: 12840029.
55. Lendel C, Bjerring M, Dubnovitsky A, Kelly RT, Filippov A, Antzutkin ON, et al. A hexameric peptide barrel as building block of amyloid-β protofibrils. Angew Chem Int Ed Engl. 2014; 53(47): 12756-60. Epub 2014/09/27. doi: 10.1002/anie.201406357 PMID: 25256598.
56. Jan A, Adolfsson O, Allaman I, Buccarello AL, Magistretti PJ, Pfeifer A, et al. Aβ42 neurotoxicity is mediated by ongoing nucleated polymerization process rather than by discrete Aβ42 species. The Journal of biological chemistry. 2011; 286(10): 8585-96. Epub 2010/12/16. doi: 10.1074/jbc.M110. 172411 PMID: 21156804; PubMed Central PMCID: PMC3048741.
57. Cavener DR, Ray SC. Eukaryotic start and stop translation sites. Nucleic acids research. 1991; 19 (12): 3185-92. Epub 1991/06/25. PMID: 1905801; PubMed Central PMCID: PMC328309.
58. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. Journal of American Statistical Association. 1958.